| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology (M.S., T.S., H.S.) and Molecular Biology and Applied Physiology (K.T.), Tohoku University School of Medicine, Sendai, Miyagi 980-8575, Japan; and Division of Gastroenterology and Hepatology, Departments of Internal Medicine (M.S., A.T.), and Pathology, Clinical Service (M.K.), Jikei University School of Medicine, Tokyo 105-8461, Japan
Address all correspondence and requests for reprints to: Masayuki Saruta, M.D., Department of Pathology, Tohoku University School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. E-mail: m-saruta{at}pg7.so-net.ne.jp.
Ulcerative colitis (UC) is characterized by a long-standing chronic inflammation of the bowel with intermittent periods of exacerbation and remission. Its acute exacerbation appears to be related to various stresses. Urocortin 1 (Ucn1) may play important roles in integrated local responses to stress. We therefore examined local production of Ucn1 in patients with UC by immunohistochemistry and mRNA in situ hybridization. Ucn1 immunoreactivity was predominantly detected in lamina propria plasma cells and enterochromaffin cells. In UC patients without glucocorticoid treatment, Ucn1-positive cells and plasma cells increased in proportion to the severity of inflammation (P < 0.0001). Ucn1-positive cells significantly increased in UC patients with advanced inflammatory grades, compared with a control group (P < 0.0001) and nonspecific colitis group (P < 0.0001). In glucocorticoid-treated patients, Ucn1-positive cells were significantly lower in number, compared with the nonglucocorticoid-treated group. Ucn1 mRNA was expressed in lamina propria plasma cells, and both corticotropin-releasing factor1 and corticotropin-releasing factor2(a) mRNAs were also partially coexpressed in these cells and macrophages. The present study showed that Ucn1-positive cells were correlated with the severity of inflammation in colonic mucosa with UC, and glucocorticoid treatment decreased these cells. Ucn1 therefore may act as a possible local immune-inflammatory mediator in UC.
This article has been cited by other articles:
![]() |
C Wallon, P-C Yang, A V Keita, A-C Ericson, D M McKay, P M Sherman, M H Perdue, and J D Soderholm Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro Gut, January 1, 2008; 57(1): 50 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kimura, T. Amano, H. Uehara, H. Ariga, T. Ishida, A. Torii, H. Tajiri, K. Matsueda, and S. Yamato Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G903 - G910. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C Moss, P. Anton, T. Savidge, P. Newman, A. S Cheifetz, J. Gay, S. Paraschos, M. W. Winter, M. P Moyer, K. Karalis, et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2{alpha} Gut, September 1, 2007; 56(9): 1210 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Zoumakis, D K Grammatopoulos, and G P Chrousos Corticotropin-releasing hormone receptor antagonists Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S85 - S91. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kokkotou, D. Torres, A. C. Moss, M. O'Brien, D. E. Grigoriadis, K. Karalis, and C. Pothoulakis Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J. Immunol., September 1, 2006; 177(5): 3355 - 3361. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Gonzalez-Rey, A Fernandez-Martin, A Chorny, and M Delgado Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease Gut, June 1, 2006; 55(6): 824 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gonzalez-Rey, A. Chorny, N. Varela, G. Robledo, and M. Delgado Urocortin and Adrenomedullin Prevent Lethal Endotoxemia by Down-Regulating the Inflammatory Response Am. J. Pathol., June 1, 2006; 168(6): 1921 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, Y. Xu, H. Zhou, J. Tao, and S. Li Expression of urocortin in rat lung and its effect on pulmonary vascular permeability. J. Endocrinol., April 1, 2006; 189(1): 167 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fukuda, K. Takahashi, T. Suzuki, M. Saruta, M. Watanabe, T. Nakata, and H. Sasano Urocortin 1, Urocortin 3/Stresscopin, and Corticotropin-Releasing Factor Receptors in Human Adrenal and Its Disorders J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4671 - 4678. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |